Matterhorn Biosciences AG

Matterhorn is a biotechnology company focusing on the discovery of cellular therapies targeting the MR1 molecule. MR1
presents cancer-specific metabolites on the surface of cancer cells that are recognized and killed by T cells bearing a
MR1-specific T cell receptor. Matterhorn was launched by Versant Ventures and emerged from a collaboration between
founding scientists at the University of Basel and the firm's Ridgeline Discovery Engine in Basel Switzerland.